<DOC>
	<DOCNO>NCT00887861</DOCNO>
	<brief_summary>This study asses safety efficacy BGG492 reduce seizure rate therapy-refractory partial seizure .</brief_summary>
	<brief_title>Efficacy BGG492 Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation Epilepsy Surgery</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>1 . A diagnosis partial seizure ( without secondary generalization ) undergo evaluation epilepsy surgery , base classification International League Against Epilepsy ( ILAE ) , modified 1981 . 2 . Absence evolve spaceoccupying lesion progressive neurological disease . 3 . Have normal vital sign ( systolic diastolic blood pressure pulse rate ) 4 . All female subject must negative pregnancy test result 5 . Subjects must weigh least 50 kg participate study must body mass index ( BMI ) within range 18 35 . 1 . A history frequent and/or severe status epilepticus ( i.e . require intensive care unit treatment ) . 2 . Current treatment phenobarbital , primidone zonisamide ( drug would completely wash study start ) 3 . Having discontinue chronic benzodiazepine barbiturate therapy within 30 day prior study start 4 . Having electrode implanted brain . 5 . Having evidence physical examination , history medically significant thyroid , cardiac , respiratory , hepatic , gastrointestinal , renal , hematologic , oncologic , psychiatric progressive neurological disorder , require current medical intervention/therapy likely significant impact outcome study . 6 . With surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug , e.g . GI surgery and/or pancreatic liver disease 7 . Having significant illness epilepsy within two ( 2 ) week prior initial dosing . 8 . Having recent ( within last three ( 3 ) year ) and/or recurrent history autonomic dysfunction ( e.g. , recurrent episode fainting , palpitation , etc ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>monotherapy trial</keyword>
	<keyword>partial seizure</keyword>
	<keyword>Partial seizure undergo evaluation epilepsy surgery</keyword>
</DOC>